A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects

Trial Profile

A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Salmeterol (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AbCONTOUR1
  • Sponsors Neothetics
  • Most Recent Events

    • 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2015 Primary endpoint has not been met. (Change in the patient reported photonumeric score), as per Neothetics media release.
    • 14 Dec 2015 Primary endpoint has not been met. (Change in the clinician reported global abdominal perception score), as per Neothetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top